| Bioactivity | HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor (IC50=0.009 μM). HDAC6-IN-42 shows significant anti-leukemia activity and synergistic effect with Decitabine (HY-A0004). HDAC6-IN-42 can be used for the AML research[1]. |
| Invitro | HDAC6-IN-42 对 3 种白血病细胞株 (HAL01：2.32±0.77 μM，HL60：2.04±0.62 μM，Jurkat：3.08±0.59 μM)的抗增殖活性比HPOB 提高 5 倍以上[1]。HDAC6-IN-42 对 HDAC6 具有更高的选择性 (IC50=0.787 μM；SIHDAC2/6=87) 和 HDAC3 (IC50=0.520 μM；SIHDAC3/6=58) 与 HDAC1 相比 (IC50=0.228 μM；Sihdac1/6=25)[1]。HDAC6-IN-42 (1.5 μM；48 h) 对健康成纤维细胞表现出没有细胞毒性，并表现出晚期凋亡细胞百分比的显著增加[1]。HDAC6-IN-42 在诱导与 Decitabine (HY-A0004) 特异性药物协同作用对抗 AML 细胞方面表现出色[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> HDAC6-IN-42 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| Formula | C24H28FN3O4 |
| Molar Mass | 441.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tretbar M, et al. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine[J]. European Journal of Medicinal Chemistry, 2024: 116447. |